We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Communication Can Minimize Study Disruptions During IRB Transfers: FDA
Communication Can Minimize Study Disruptions During IRB Transfers: FDA
June 15, 2012
To smoothly transition clinical investigation oversight from one institutional review board to another, devicemakers, contract research organizations (CRO), new and old IRBs and clinical investigators should work closely to minimize disruptions to the ongoing trial and ensure subjects are constantly protected, according to an FDA draft guidance.